Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$90.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Etherington
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 78
- Beta
- 0.95
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -23.04
Financials
Revenue
$90.0K+28.6%Net Income
$-13.42MEBITDA
$-4.99MFree Cash Flow
$-2.59MEPS (diluted)
$-1.08Shares Outstanding (diluted)
12.38M+296.7%Operating Expenses
$5.40MCash & Debt
$9.67MRevenue by Segment (annual)
$200.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $200.0K | $-26.17M | $-2.65 |
| 2024 | $342.0K | $-39.40M | $-5.67 |
| 2023 | $654.0K | $-49.50M | $-9.43 |
| 2022 | $473.0K | $-29.92M | $-4.69 |
| 2021 | $723.0K | $-9.74M | $-3.16 |
| 2020 | $206.0K | $-19.28M | $-5.51 |
| 2019 | $0.00 | $-16.16M | $-4.69 |
| 2018 | $0.00 | $-277.3K | $-0.09 |
| 2017 | $0.00 | $-2.4K | $-0.00 |
Valuation
CLNNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10+0.00%Social Signal Score
Mentions (9)
- Newsmarketbeat.com·4d ago·Negative
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision Clene NASDAQ: CLNN said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Clene to Present at Upcoming Investor Conferences SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences.
View source ↗ - Newsglobenewswire.com·15d ago·Negative
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the closing of a registered direct offering of common stock to existing shareholders, including insiders, with total gross proceeds of $4 million.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Clene to Present at Upcoming September Investor Conferences SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C.
View source ↗ - Newsmarketbeat.com·47d ago·Negative
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an interview.
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19, 2026 Time of Presentation: 3:10 p.m.
View source ↗ - Newszacks.com·52d ago·Neutral
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.78 per share a year ago.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…es survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. “We plan to submit our new drug application (NDA) for CNM-Au8 under the accelerated approval pathway for patients with ALS and believe the evidence connecting the magnitude of NfL reduction to clinical benefit data we…
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.46 per share
Typical surprise -38.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-1.08 vs $-0.37miss
- Thu, May 14$-0.69 vs $-0.50miss
- Thu, Mar 12$-0.93 vs $-0.74miss
- Thu, Nov 13$-0.85 vs $-0.60miss
- Thu, Aug 14$-0.78 vs $-0.49miss
- Wed, May 7$-0.09 vs $-0.95beat
Estimates and results for CLNN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLNN officers and directors.
- Bought
- $217k
- Sold
- $4.0m
1 trade
47 trades
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
- Ugwumba Chidoziesold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLNN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.